Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation & Amortization (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 23.61% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 23.61% year-over-year, with the annual reading at $8.9 million for FY2025, 23.61% up from the prior year.
  • Accumulated Depreciation & Amortization hit $8.9 million in Q4 2025 for Rocket Pharmaceuticals, up from $2.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.9 million in Q4 2025 to a low of $1.1 million in Q1 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged $4.1 million across 5 years, with a median of $3.7 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: crashed 85.0% in 2023 and later skyrocketed 350.0% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $3.2 million in 2021, then rose by 21.88% to $3.9 million in 2022, then increased by 25.64% to $4.9 million in 2023, then skyrocketed by 46.94% to $7.2 million in 2024, then grew by 23.61% to $8.9 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for RCKT at $8.9 million in Q4 2025, $2.7 million in Q3 2025, and $4.5 million in Q2 2025.